About Applied Genetics Technologies Corporation
Applied Genetics Technologies Corporation is a Healthcare company based in Alachua (United States) founded in 1999, and was acquired by Syncona in October 2022. Developer of gene therapies for rare eye diseases caused by mutated genes. Applied Genetics Technologies Corporation has raised $98.85 million across 10 funding rounds from investors including Syncona, HHS and Alta Partners. The company has 83 employees. Applied Genetics Technologies Corporation offers products and services including AAV Gene Therapy. Its focus areas include Life Sciences, Rare Diseases, Drugs and Ophthalmology Diseases. Its legal entity is APPLIED GENETIC TECHNOLOGIES CORPORATION. Its competitors include BridgeBio, Spark Therapeutics and Alnylam; 3 of its 3 listed competitors have raised funding.
Company details
Applied Genetics Technologies Corporation was founded in 1999 in Alachua, United States, within the biotechnology sector. Focus is placed on developing gene therapies for rare ophthalmologic conditions caused by genetic mutations, including lead programs in Achromatopsia, X-Linked Retinoschisis, and X-Linked Retinitis Pigmentosa. An adeno-associated virus-based delivery system is employed for these therapies, targeting orphan diseases in ophthalmology. Operations center on advancing clinical-stage gene therapy solutions.
Products & Services of Applied Genetics Technologies Corporation
Applied Genetics Technologies Corporation offers a comprehensive portfolio of products and services, including AAV Gene Therapy.
Delivers functional genes to treat genetic retinal diseases effectively.
Funding Insights of Applied Genetics Technologies Corporation
Applied Genetics Technologies Corporation has successfully raised a total of $98.85M across 10 strategic funding rounds. The most recent funding activity was a Grant round of $444.06 thousand completed in September 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $98.85M
- Total Rounds 10
- Last Round Grant — $444,061
- First Round $15.25M
(Dec 2003)
- Investors Count 8
All 10 funding rounds of Applied Genetics Technologies Corporation with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2013 | $444,061 | Grant | – | – | |
| Nov 2012 | $37.5M | Series B | – | Alta Partners, SR One | |
| May 2012 | $750,000 | Series B | – | – | – |
| Sep 2010 | $1M | Grant | – | – | – |
| Sep 2010 | $2.13M | Grant | – | – | |
| Jun 2010 | $143,082 | Grant | – | – | |
| May 2010 | $143,082 | Grant | – | – | |
| Jul 2009 | $33.55M | Series B | – | – | – |
| Apr 2009 | $11.8M | Series A | – | InterWest Partners | |
| Dec 2003 | $15.25M | Series A | – | InterWest Partners |
9 investors in total: 9 institutional.
Investors in Applied Genetics Technologies Corporation
Applied Genetics Technologies Corporation has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Syncona, HHS and Alta Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm focused on healthcare companies | altapartners.com | Jackson, United States | ||
Early-stage investing in IT and healthcare ventures. | interwest.com | |||
Early-stage life sciences and tech focused VC firm funding companies in the US | intersouth.com | Durham, United States | ||
| medimmuneventures.com | ||||
A biotechnology venture capital firm investing in innovative science. | srone.com | |||
Early- to growth-stage startups are targeted for venture capital investments. | oup.vc | Bala Cynwyd, United States | ||
US life sciences companies are invested in by Skyline Ventures. | skylineventures.com | Palo Alto, United States | ||
Healthcare investments are managed via private equity by Syncona. | 2012 | synconaltd.com | London, United Kingdom | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for Applied Genetics Technologies Corporation
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Applied Genetics Technologies Corporation
30 people are tracked at Applied Genetics Technologies Corporation (4 in leadership, 26 in board & advisors); the tracked headcount is 83.
| Name | Role | Group |
|---|---|---|
Dave Fellows | CEO | Leadership |
Jerry Reynolds | Chief Accounting Officer & Treasurer | Leadership |
Nadia Waheed | Chief Medical Officer | Leadership |
Tracy Riggins | Senior Director Human Resources | Leadership |
Barry Byrne | Founder & Scientific Advisor | Board & advisors |
Nicholas Muzyczka | Founder & Scientific Advisor | Board & advisors |
David G. Birch | Scientific Advisor | Board & advisors |
Richard G. Weleber | Scientific Advisor | Board & advisors |
David M. Brown | Scientific Advisor | Board & advisors |
Terence Flotte | Founder & Scientific Advisor | Board & advisors |
R. Jude Samulski | Founder & Scientific Advisor | Board & advisors |
Karl G. Csaky | Scientific Advisor | Board & advisors |
Gregory S. Hageman | Scientific Advisor | Board & advisors |
J. Timothy Stout | Scientific Advisor | Board & advisors |
Peter A. Campochiaro | Scientific Advisor | Board & advisors |
Wade W. Chien | Scientific Advisor | Board & advisors |
Stephen P. Daiger | Scientific Advisor | Board & advisors |
William W. Hauswirth | Scientific Advisor | Board & advisors |
Paul Kaufman | Scientific Advisor | Board & advisors |
Karen B. Avraham | Scientific Advisor | Board & advisors |
10 more people are available in the full profile.
Complete people profiles for Applied Genetics Technologies Corporation
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Applied Genetics Technologies Corporation
5 dated milestones of Applied Genetics Technologies Corporation across 23 years, from founding to its latest funding, stage changes and deals.
- Founded Applied Genetics Technologies Corporation is founded.
- Funding First funding round of $15.2M.
- Funding Latest funding round, Grant, of $444K.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by Syncona.
Competitors of Applied Genetics Technologies Corporation
Applied Genetics Technologies Corporation has 3 listed competitors in our database, 3 of them funded. They include BridgeBio, Spark Therapeutics and Alnylam.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. | |
| alnylam.com | 2002 | Cambridge, United States | $17M | 2,100 | RNA interference-based therapeutics are developed for multiple disorders. |
Detailed competitors of Applied Genetics Technologies Corporation
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Applied Genetics Technologies Corporation
Websites that share an audience with Applied Genetics Technologies Corporation (agtc.com).
Websites whose visitors overlap most with Applied Genetics Technologies Corporation. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| mapmygene.com | 100% | #8,021,007 | View details | ||
clingensoc.org | clingensoc.org | 98% | #7,675,611 | – | |
omim.org | omim.org | 98% | #90,018 | – |
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Applied Genetics Technologies Corporation (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Applied Genetics Technologies Corporation
Complete news archive for Applied Genetics Technologies Corporation
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Applied Genetics Technologies Corporation
Applied Genetics Technologies Corporation was founded in 1999 and raised its 1st funding round 4 years after it was founded.
Applied Genetics Technologies Corporation is headquartered in Alachua, United States. It is registered at Alachua, Florida, United States.
Applied Genetics Technologies Corporation is a funded company, having raised a total of $98.85M across 10 funding rounds to date. The company's 1st funding round was a Series A of $15.25M, raised on Dec 2003.
Applied Genetics Technologies Corporation has 83 employees.
Applied Genetics Technologies Corporation was founded in 1999 in Alachua, United States, within the biotechnology sector. Focus is placed on developing gene therapies for rare ophthalmologic conditions caused by genetic mutations, including lead programs in Achromatopsia, X-Linked Retinoschisis, and X-Linked Retinitis Pigmentosa. An adeno-associated virus-based delivery system is employed for these therapies, targeting orphan diseases in ophthalmology. Operations center on advancing clinical-stage gene therapy solutions.
Applied Genetics Technologies Corporation's top competitors include Spark Therapeutics, BridgeBio and Alnylam.
Applied Genetics Technologies Corporation offers AAV Gene Therapy.
Applied Genetics Technologies Corporation has 9 investors. Key investors include Syncona, HHS, Alta Partners, InterWest, and Intersouth Partners.
Applied Genetics Technologies Corporation operates through Applied Genetic Technologies Corporation.
Yes. Applied Genetics Technologies Corporation was acquired by Syncona in October 2022.